EPIC-Peds：入院はしていないが重症化リスクのある18歳未満のCOVID-19患者を対象に、PF-07321332（ニルマトレルビル）/リトナビルという治験薬の効果を調べる研究

基本情報

NCT ID

NCT05261139

ステータス

募集中

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

160

治験依頼者名

Pfizer

概要

The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study treatment works in the study) of the study medicine (called nirmatrelvir/ritonavir) for potential treatment of coronavirus disease 2019 (COVID-19). The study medicine will be given to patients under 18 years of age with COVID-19 that are not hospitalized but are at risk for severe disease.

対象疾患

介入

依頼者（Sponsor）

実施施設 (2)